CardiaTec is a TechBio business that uses computational tools to unravel the biology underlying cardiovascular illness. CardiaTec uses massive and high-dimensional human omics data to better understand complicated disease biology and identify novel and differentiated therapies.
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.
InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.
Neuroute (neuroute.ai) is the AI-powered system for smarter clinical trials. Backed by PharmStars (Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche & Eli Lilly). Website Neuroute.ai
Neuroute (neuroute.ai) is the AI-powered system for smarter clinical trials. Backed by PharmStars (Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche & Eli Lilly). Website Neuroute.ai
Healthcare demand is rapidly outpacing capacity, the only way to solve this is early detection & prevention. We are building a Clinical Co-pilot that supports clinicians identify patient health changes earlier. We do this by combining healthcare data and translating it into powerful insights that support clinical decision-making (SaMD's :-). Long term vision is to build a human digital twin that understands everyone's health and informs clinicians (via the Clinical Co-pilot) about your health changes. Our secret sauce is a multimodal generative AI platform that translates any type of data streams into clinical insights and easily integrates into clinical workflows and IT systems.
Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers such as the blood-brain barrier (BBB). PolyNaut, a versatile nano-engineered polymer technology that facilitates intracellular delivery, is used in collaboration with a number of partners. SomaServe is breaking new ground in the development of medications that can bypass various biological barriers and provide significant therapeutic benefits thanks to this technology.
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer.
Privitar is an enterprise software company with a global client-base across North America, Europe, and Asia. The company is the development and adoption of privacy engineering technology enabling its customers to innovate and leverage data with an uncompromising approach to data privacy. Its software is designed to allow clients to analyze potentially sensitive data while respecting customers’ privacy and confidentiality, resulting in the ability to leverage large, sensitive data sets while ensuring compliance with regulations (such as GDPR, CPRA and HIPAA) and ethical data principles.Privitar was founded in 2014 and is based in London, UK.
Qkine manufactures high-purity, animal-free growth factors, cytokines and other complex proteins. Based on the Cambridge Science Park, UK, we combine proprietary protein production processes developed at the University of Cambridge with protein engineering techniques to develop unique products that tackle fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine and cultivated meat sectors. Qkine has an active R&D pipeline, with a continually expanding product range. Unique products available from Qkine include tag-free thermostable FGF-2 (FGF2-G3), the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF (NK1). Qkine is an ISO 9001: 2015 certified company.
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.
Neurofenix is aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims.
InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer.
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers such as the blood-brain barrier (BBB). PolyNaut, a versatile nano-engineered polymer technology that facilitates intracellular delivery, is used in collaboration with a number of partners. SomaServe is breaking new ground in the development of medications that can bypass various biological barriers and provide significant therapeutic benefits thanks to this technology.
Metrion Biosciences is a specialist ion channel contract research organisation providing drug discovery services to pharmaceutical and bioscience customers worldwide.
Deepmatter Group Plc is a big data and analysis company which has built a platform - DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research, fine chemicals, scientific publications and teaching. Deepmatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™.
Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants. Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics. During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies. About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease. About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset. The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO. *source: https://nei.nih.gov/health/diabetic/retinopathy
Developing the next generation of antibiotics with novel mechanisms of action.
Stemnovate is a unique, innovative drug development platforms enable the right patients to be targeted with the right treatments, at the right time.
Equity Crowdfunding in 2017
Absynth Biologics has been created with the initial goal of developing immunological prophylaxis and therapy to combat bacterial infections. Absynth’s strategy is to exploit the characterisation of carefully selected novel proteins Staphylococcus aureus (S. aureus)in bacteria as immunological targets.
Heartfelt Technologies exists to help patients, their families, carers and doctors, to reduce hospital re-admission rates from congestive heart failure de-compensation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.